Glaukos : Investor Presentation May 2024

Investor Presentation

May 2024

Disclaimer

All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business or the economy; the impact of general macroeconomic conditions including foreign currency fluctuations; the reduced physician fee and ASC facility fee reimbursement rate finalized by CMS for 2022 and 2023 for procedures utilizing the Company's iStent family of products and its impact on our U.S. combo-cataract glaucoma revenue; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single- source, for components of our products; the occurrence of a crippling accident, natural disaster, pandemic or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the iStent®, the iStent inject® W, iAccess, iPRIME, iStent infinite, iDose® TR, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our ability to compete effectively in the highly competitive and rapidly changing medical device industry and against current and future technologies (including MIGS technologies); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness.

These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, which was filed with the SEC on May 3, 2024. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this presentation are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

© 2024 Glaukos Corporation 2

The iDose® TR Journey

Nearly two decades of investment and commitment

134K

15+

YEARS

of research and development to bring iDose TR from ideation to commercialization

$600+

MILLION

invested in R&D

since 2018 to

advance iDose TR

and other

innovations,

representing 30%+

of revenues

1150

SUBJECTS

studied in Phase 3

FDA iDose TR

clinical trials that

met both CDRH

and CDER

requirements

SQ FEET

build-out of

iDose TR

manufacturing

facilities that meet

appropriate

regulatory, CMC and

ISO 7 guidelines

100K+

PAGES

in NDA

submission to

CDRH and CDER for FDA approval of iDose TR

© 2024 Glaukos Corporation 3

iDose TR is FDA-approved

Our pioneering journey is just beginning

Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity

First-everlong-duration procedural pharmaceutical designed to deliver up to 3 years of glaucoma drug therapy

© 2024 Glaukos Corporation 4

iDose TR: Groundbreaking Glaucoma Advancement

INDICATIONS AND USAGE

iDose TR is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)

<0.5mm

1.8mm

Unique Drug Formulation

75 mcg of a novel, proprietary, preservative-freetravoprost formulation; ~25,000x more concentrated than leading PGA medications (0.004% in Travatan Z)

Novel Membrane

Nanoporous, ethylene-vinyl acetate (EVA) membrane designed for continuous drug elution

Designed to provide 24/7, continuous, long- duration drug therapy to address ubiquitous patient non-compliance with topical medications

Insertion System	Fixed and Stable
Precision-engineered to facilitate	Securely anchored into scleral
straightforward implantation	tissue for drug elution directly
	into the anterior chamber

© 2024 Glaukos Corporation 5

iDose TR: Addresses Important Clinical Needs

High rates of non-compliance and non-adherence to topical medications contribute to disease progression

Topical medications are the dominant treatment plan for the roughly 18M US eyes1 affected by glaucoma and ocular hypertension

Research2 shows that	& ~ 5 0 %
> 9 0 %
of patients are non-compliant	purposely discontinue their
with medication use	medication(s) within 6 months

Complex dosing regimens, instillation difficulties and chronic side effects associated with topical meds undermine patient compliance and quality of life

• Hyperemia
• Periorbital fat atrophy
• Ocular surface disease
• Hyperchromia

1 Based on company analysis of Market Scope, Medicare Claims and IMS Health Compliance data. 2 Nordstrom BL, Friedman DS, Mozaffari E, Quigley H, Walker AM. Persistence and adherence with topical	© 2024 Glaukos Corporation 6
glaucoma therapy. Am J Ophthalmol. 2005;140(4): 598-606

iDose TR: Phase 3 Data Validates Game-Changing Potential

IOP REDUCTIONS FROM BASELINE OBSERVED DURING FIRST 3 MONTHS1

iDose TR

Timolol 0.5% BID

Baseline (mmHg)	8.5	8.4
	7.7
from
IOP Reductions			7.2
6.6	6.7	6.8
	6.5

In 2 pivotal trials (1,150 subjects randomized across both trials), iDose TR achieved pre-specified primary efficacy endpoints as agreed upon with US FDA(non-inferiority to topical timolol through 3 months)

IOP VALUES ON PRE-STUDY PGAs, AFTER PGA WASHOUT AND AT 3 MONTHS OF iDOSE TR

	24			In-Study iDose
		Pre-study	23.8	• 125 subjects across both Phase 3 trials
	22	TR:	were on single PGA IOP-lowering med
	PGAs:	mmHg	-7.1 mmHg
		at screening
		-5.8 mmHg		(Δ 1.3 mmHg
	20			vs pre-study	• After 4-week washout, IOP rose to 23.8
				PGAs,	mmHg, showing pre-studyPGA
				p = 0.0003)
	18			efficacy of -5.8 mmHg
(mmHg)	18.0
		16.7	• After iDose TR administration, IOP
IOP	16	mmHg		decreased to 16.7 mmHg at 3 months,
			mmHg	showing iDose TR in-study efficacy of
	14			-7.1 mmHg
	12				• iDose TR demonstrated 1.3 mmHg
				statistically significant superior IOP-
					lowering vs pre-study PGAs (p =
	10	Pre-Study PGA	After Washout (Remove		0.0003)
			pre-study PGA)	Month 3

Statistically significant superior IOP-lowering vs pre-study PGAs in sub-group analysis of combined Phase 3 trials

1 mmHg range represents IOP reduction means across the 6 US FDA pre-specified timepoints of 8AM and 10AM at Day 10, Week 6 and Month 3	© 2024 Glaukos Corporation 7

iDose TR: Phase 3 & Phase 2b Data Confirms Long Duration

81% of iDose TR subjects in the Phase 3 trials were completely free of IOP-lowering topical medications at 12 months

• OF iDOSE TR SUBJECTS WELL-CONTROLLED1 ON THE SAME OR FEWER IOP-
  LOWERING TOPICAL MEDICATIONS

	AT 12 MONTHS	AT 24 MONTHS	AT 36 MONTHS
PH 3	93%

PH 2B	92%	72%	69%

• PATIENTS WELL CONTROLLED1 ON THE SAME OR FEWER TOPICAL IOP-LOWERING MEDS IN PHASE 2B TRIAL AT 3 YEARS

69%

45%

Timolol

0.5% BID

1 Well-controlled patients were prospectively defined in the clinical study protocol as those with IOP ≤ 18 mmHg in the Phase 2B trial. In the Phase 3 trials, they were defined as those with	© 2024 Glaukos Corporation 8
IOP ≤ 22 mmHg, or > 22 and ≤ 25 mmHg with a reduction of ≥ 20% from baseline. Patients above these values were treated with the addition of a topical IOP-lowering medication

iDose TR: Pharmacokinetic Clinical Study Results

iDose TR shown to deliver therapeutically relevant and durabledrug concentrations through 24 months

Open label, single-center study to determine in-patient drug elution rate and aqueous humor (AH) exposure to travoprost free acid (TFA)

210 iDose TR patients were followed for 3-24 months

At pre-determined timepoints, iDose TR was removed and analyzed for remaining levels of travoprost in the implants. AH was collected and analyzed for TFA concentrations

MEAN TFA CONCENTRATIONS

5.0	3.7	5.6	3.8	3.3
ng/mL		2.0	2.2
	3 Months	6 Months 12 Months 15 Months	18 Months 21 Months	24 Months

AVG AMOUNT OF TRAVOPROST REMAINING FOLLOWING EXPLANTATION

TravoprostOf	79%	70%			28%
		50%	39%	35%
				16%
%
	3 Months 6 Months 12 Months 15 Months	18 Months 21 Months 24 Months

Mean TFA levels were above CMAX concentration of TFA (1.78 ng/mL) determined after the dosing of topical travoprost; levels were also above efficacious TFA level (95 pg/mL) estimated after intracameral implant dosing of travoprost

At 24 months, iDose TR implants still contained 16% of the travoprost drug product

Data abstract accepted for presentation at ARVO 2024 Annual Meeting	© 2024 Glaukos Corporation 9

iDose TR: Phase 3 & Phase 2b Results Show Excellent Safety

PHASE 3 AND PHASE 2B SAFETY DATA

	Ph 3 Trials	Ph 2b Trial	Topical PGAs
	1 Year	3 Years

No adverse events of	Up to 70% incidence
periorbital fat atrophy
Very low conjunctival	30%-50% incidence
hyperemia
No adverse events of corneal
endothelial cell loss
Very low or no incidence of	~20% incidence
iris color change

FDA APPROVAL: PRESCRIBING SAFETY INFORMATION

In controlled studies, the most common ocular adverse reactions in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, and visual field defects.

© 2024 Glaukos Corporation 10